US Stock MarketDetailed Quotes

NVO Novo-Nordisk A/S

Watchlist
  • 107.200
  • -0.430-0.40%
Close Nov 8 16:00 ET
  • 107.250
  • +0.050+0.05%
Post 20:01 ET
477.70BMarket Cap34.91P/E (TTM)

About Novo-Nordisk A/S Company

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsv?rd, Denmark.

Company Profile

SymbolNVO
Company NameNovo-Nordisk A/S
Listing DateJul 9, 1981
Founded1931
CEOMr. Lars Fruergaard Jorgensen
MarketNYSE
Employees64319
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
AddressNovo Allé 1
CityBagsv?rd
ProvinceCapital Region
CountryDenmark
Zip Code2880
Phone45-44-44-88-88

Company Executives

  • Name
  • Position
  • Salary
  • Lars Fruergaard Jorgensen
  • Chief Executive Officer and President
  • --
  • Marcus Schindler, PhD
  • Executive Vice President, Research and Early Development and Chief Scientific Officer
  • 23.60M
  • Karsten Munk Knudsen
  • Executive Vice President and Chief Financial Officer
  • 26.40M
  • Camilla Sylvest
  • Executive Vice President, Commercial Strategy and Corporate Affairs
  • 23.40M
  • Ludovic Helfgott
  • Executive Vice President, Rare Disease
  • 2.20M
  • Henrik Ehlers Wulff
  • Executive Vice President, Product Supply, Quality Assurance, Digital Data and IT
  • 25.90M
  • Doug Langa
  • Executive Vice President, North America Operations
  • 2.20M
  • Maziar Mike Doustdar
  • Executive Vice President, International Operations
  • 2.20M
  • Martin Holst Lange
  • Executive Vice President, Development
  • 23.40M
  • Henrik Poulsen
  • Vice Chairman of the Board
  • 2.40M
  • Helge Lund
  • Chairman of the Board
  • 3.90M
  • Liselotte Hyveled
  • Director
  • 1.10M
  • Elisabeth Dahl Christensen
  • Director
  • 1.10M
  • Mette Bojer Jensen
  • Director
  • 1.30M
  • Kasim Kutay
  • Director
  • 1.30M
  • Thomas Rantzau
  • Director
  • 1.10M
  • Laurence Debroux
  • Independent Director
  • 2.10M
  • Christina Law
  • Independent Director
  • 1.70M
  • Dr. Martin W. Mackay, PhD
  • Independent Director
  • 1.80M
  • Andreas Fibig
  • Independent Director
  • 1.40M
  • Dr. Sylvie Gregoire,Pharm.D.
  • Independent Director
  • 2.00M
  • Tania Sabroe
  • Executive Vice President, People and Organisation
  • 2.20M
  • David Moore
  • Executive Vice President, Corporate Development
  • 2.20M

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data